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Solar-simulated ultraviolet radiation (ssUV) suppresses immunity in humans. The ultraviolet B (UVB) waveband is
recognized as immunosuppressive; however the relative significance of UVA to ssUV immunosuppression is un-
known. We created dose and time–response curves for UVB-, UVA-, and ssUV-induced suppression of memory
immunity to nickel in humans. UVB caused immunosuppression within 24 h. UVA immunosuppression required 48
h and was normalized by 72 h. UVB alone accounts for ssUV immunosuppression at 24 h, but both UVB and UVA
contributed at 48 h. By 72 h neither waveband accounted for ssUV immunosuppression. An interaction between
these wavebands was therefore the major contributor. To conﬁrm this dose–response curves were used to de-
termine immune protection factors (IPF) for sunscreens with nickel challenge 72 h following ssUV. A sunscreen
with good UVA protection had an IPF twice that of a poor UVA protector, despite providing similar protection from
sunburn. Thus UVA was a major contributor to ssUV-induced immunosuppression at 72 h but only with the co-
operation of UVB. Hence, UVB initiates immunosuppressive signals within 24 h, followed by UVA at 48 h, then an
interaction between UVB and UVA. By 72 h following ssUV exposure, neither UVB nor UVA, but an interaction
between them is the major cause of sunlight-induced immunosuppression.
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Skin cancer continues to be a major worldwide healthcare
issue and is largely caused by ultraviolet (UV) radiation in
sunlight (de Gruijl, 1999). Not only does UV induce genetic
mutations (Wikonkal and Brash, 1999), but also the impor-
tance of UV-induced suppression of cell-mediated immunity
is well established in photocarcinogenesis (Beissert and
Schwarz, 1999). The increased incidence of non-melanoma
skin cancers in chronically immunosuppressed transplant
populations further supports the role of cell-mediated im-
munity in tumor surveillance (Lindelof et al, 2000).
The relative roles of the UVA (320–400 nm) and UVB
(290–320 nm) wavebands in sunlight-induced cutaneous
immunosuppression are unclear, particularly in humans. Al-
though it is generally accepted that UVB suppresses both
contact hypersensitivity (CHS) and delayed-type hypersen-
sitivity (DTH) responses in humans and animal models, the
role of UVA is more controversial. In some studies UVA has
been found to suppress the induction of local primary im-
munity in mice (Bestak and Halliday, 1996), but others have
suggested that UVA does not suppress the immune system,
but protects from UVB (Reeve et al, 1998). UVA has also
been shown to suppress the reactivation of memory immu-
nity in mice (Nghiem et al, 2001) and humans (Damian et al,
1999; Moyal and Fourtanier, 2001; Kuchel et al, 2002). Re-
cent studies have shown that immunomodulation is de-
pendent on the dose of UVA used; with moderate doses
being immunosuppressive and higher doses immunopro-
tective (Byrne et al, 2002).
Sunscreen studies have further delineated the role of
UVA in solar-simulated ultraviolet (ssUV) -induced immuno-
suppression. Studies in mice (Bestak et al, 1995) and hu-
mans (Damian et al, 1997; Kelly et al, 2003; Wolf et al, 2003)
have determined that broad-spectrum sunscreens that pro-
tect from both UVA and UVB provide better defense against
ssUV suppression of CHS than UVB only protective sun-
screens. Similarly, sunscreens with higher UVA protection
factors have improved protection of the elicitation of DTH
responses than sunscreens with low levels of UVA protec-
tion (Fourtanier et al, 2000). We have recently demonstrated
that immune protection by sunscreens does not correlate
with protection of erythema, and that the level of sunscreen
UVA protection is important for determining the level of
immune protection from ssUV (Poon et al, 2003). This
indicates that the UVA waveband within ssUV,
either independently or in a manner that it dependent on
UVB, is an important contributor to ssUV-induced immuno-
suppression.
Few studies have addressed the comparative impor-
tance of UVB and UVA in sunlight, or ssUV-induced
immunosuppression. This is an unresolved issue, particu-
larly in humans. To address this we have adapted our model
of repetitive exposure ssUV-induced suppression of the
Abbreviations: CHS, contact hypersensitivity; DTH, delayed-type
hypersensitivity; IPF, immune protection factor; LC, Langerhans
cells; MISD, minimum immunosuppressive dose; SPF, sun protec-
tion factor; ssUV, solar simulated ultraviolet radiation; UV, ultravi-
olet radiation; UVA-PF, UVA protection factor.
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reactivation of memory immunity to nickel in humans (Dam-
ian and Halliday, 2002) to a single irradiation protocol. This
has enabled us to determine time and dose–response
curves for UVA-, UVB- and ssUV-induced immunosuppres-
sion. We have also used sunscreens with low and high UVA
protective capability to remove the contribution of UVB from
ssUV-induced immunosuppression. These studies show
that UVB initiates the earliest immunosuppressive signals
from ssUV, within 24 h, and that UVA is also immunosup-
pressive, but not until 48 h following exposure. By 72 h
following exposure an interaction between these two wave-
bands makes ssUV much more suppressive than either
waveband independently.
Results
Time course and dose–response of UV-induced im-
munosuppression UVB caused a dose-related immuno-
suppression. Antigen challenge 24 h after irradiation caused
significant immunosuppression at 500 mJ per cm2 UVB,
whereas antigen challenge 48 and 72 h after irradiation
caused significant immunosuppression at 300 and 500 mJ
per cm2 (Fig 1). Therefore the biological changes caused by
UVB that lead to immunosuppression occurred within the
first 24 h following irradiation and were maintained for at
least 72 h.
The response to UVA differed from UVB. The doses used
were the relative amounts present in ssUV that correspond-
ed to each UVB dose, 7.7 times the UVB doses. UVA did not
cause significant immunosuppression at any dose tested
when antigen was applied 24 h after irradiation (Fig 1). An-
tigen challenge 48 h following UVA exposure caused sig-
nificant immunosuppression at 2310 and 3850 mJ per cm2.
When the time between UVA exposure and antigen chal-
lenge was increased to 72 h, significant immunosuppres-
sion was not observed at any dose tested. Therefore the
biological changes caused by UVA that lead to immuno-
suppression take longer to develop than for UVB, and also
recover more rapidly so that immunosuppression is only
observed over a narrow time frame between irradiation and
antigen challenge.
The response to ssUV differed from both UVB and UVA.
The ssUV doses contained the amounts of UVB and UVA
that had been tested separately (i.e., 1740 mJ per cm2 ssUV
comprised of 200 mJ per cm2 UVB and 1540 mJ per cm2
UVA). Antigen challenge 24 or 48 h following ssUV caused
significant immunosuppression only at the highest dose
tested, 4350 mJ per cm2. In contrast, when the time be-
tween ssUV exposure and antigen was increased to 72 h,
significant immunosuppression was observed at all doses
tested; even the lowest dose caused significant immuno-
suppression (Fig 1). Thus ssUV-induced immunosuppres-
Figure 1
Single-exposure ultraviolet (UV) immunosuppression time course
and dose response. In separate experiments groups of 15 nickel-
allergic volunteers were irradiated with a single exposure to UVB, UVA
or solar-simulated UV (ssUV). Nine different areas on the lower back of
each volunteer received one of three UV doses at each of 24 h (open
columns), 48 h (hatched columns) and 72 h (closed columns) prior to
nickel challenge to generate dose and time responses for each of the
three UV spectra. The UVA and UVB doses used were their relative
contributions to the ssUV dose. The resultant erythema from the nickel
CHS response at each irradiated site was read 72 h after nickel chal-
lenge using an erythema meter and subtracted from an unirradiated
positive control site to calculate immunosuppression (erythema index).
Mean  SEM are shown for the 15 volunteers. A paired two-tailed
Student’s t test was used to compare each test site with the unirra-
diated control to determine whether the immunosuppression at each
dose was significant, and this is shown by the p value centerd above
each column.
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sion is considerably greater when antigen is not applied
until 72 h following ssUV exposure.
The shape of the spectral curve for UVB closely matched
the UVB portion of the ssUV spectrum and the shape of the
spectral curve for UVA closely matched the UVA portion of
the ssUV spectrum above 340 nm (Fig 2). Thus it is rea-
sonable to compare the results from the different spectra.
But, as UVB, UVA, and ssUV were tested in different ex-
periments on separate groups of volunteers, the magnitude
of the responses cannot be directly compared between
experiments as the groups may have different sensitivities
to UV. Relationships within an experiment, however, can be
analyzed further. At 24 h ssUV was suppressive only at the
highest dose tested (4350 mJ per cm2, made up of 500 mJ
per cm2 UVB and 3850 mJ per cm2 UVA). UVB also caused
significant immunosuppression only at the highest dose of
500 mJ per cm2, the relative component of the highest ssUV
dose. UVA was not immunosuppressive at any dose tested
at 24 h. At 48 h the ssUV dose response was not signif-
icantly different from the 24 h dose response (p¼ 0.893,
repeated-measures ANOVA). UVB remained significantly
immunosuppressive at 48 h with no significant difference
from the dose response at 24 h (p¼ 0.537, repeated-meas-
ures ANOVA). UVA, however, became immunosuppressive
at 48 h with the UVA dose response being significant-
ly greater than at 24 h (p¼ 0.040, repeated-measures
ANOVA). Thus ssUV-induced immunosuppression 24 h fol-
lowing antigen challenge is primarily caused by UVB, but at
48 h is because of both UVB and UVA being independently
immunosuppressive.
At 72 h the ssUV-induced dose response increased sig-
nificantly compared with 24 h (p¼ 0.007, repeated-meas-
ures ANOVA) and 48 h (p¼0.016). This contrasts with the
UVB dose response at this time, which did not significantly
change compared with either the 24 h (p¼0.322) or
48 h UVB dose responses (p¼0.409, repeated-measures
ANOVA). Additionally UVA was not immunosuppressive at
any dose at this time, and the UVA dose response de-
creased so that it was no longer significantly different from
the 24 h dose response (p¼0.205). Thus, as ssUV immuno-
suppression increased at this time, whereas the response to
the UVB waveband did not, and the response to UVA was
not suppressed, an interaction between these wavebands
appeared to be the major cause of immunosuppression at
72 h.
Immune protection factor (IPF) for sunscreen with good
UVA protection is higher than for sunscreen with poor
UVA protection In further studies, sunscreens with differ-
ent UVA-protective capacities were tested for immunopro-
tection with antigen applied 72 h following ssUV exposure.
Both sunscreens absorb greater than 95% of UVB (Fig 3).
Whereas sunscreen B maintains good absorption up to 380
nm, sunscreen A shows a sharp drop at about 320 nm to
60%, and another sharp drop to 30% at about 370 nm and
therefore does not provide as good a protection from UVA
as sunscreen B.
None of the sunscreens had any significant effect on the
nickel reaction as there was no significant difference be-
tween unirradiated untreated positive controls and unirra-
diated sunscreen-treated controls (paired Student’s t test).
The minimum immunosuppressive doses (MISD) for un-
protected sites was determined from linear regression anal-
ysis as the ssUV dose that caused 30% immunosup-
pression. Using the same cutoff, the MISD for the sun-
screen-protected sites was determined in a similar manner
(Fig 4). The IPF for each sunscreen was calculated as the
ratio of MISD (sunscreen protected) to MISD (unprotected)
in the same group of individuals. With ssUV irradiation 72 h
prior to antigen challenge, the IPF for sunscreen A (sun
protection factor (SPF) 15, poor UVA protector with a UVA
protection factor (UVA-PF) of 2.3) was determined to be
10.3 (95% confidence interval 1.6–18.3). For sunscreen B
Figure 2
Spectra used in this study. An Oriel 1000 W solar simulator equipped
with twin 280–400 nm dichroic mirrors and an atmospheric attenuation
filter produced a solar-simulated ultraviolet spectrum that closely ap-
proximates standard sunlight as defined by COLIPA. Using a ultraviolet
(UV)B/UVC-blocking filter in place of the atmospheric attenuation filter
produced a UVA spectrum. Two 280–320 nm dichroic mirrors were
used together with the atmospheric attenuation filter to produce the
UVB spectrum. The ssUV, COLIPA, and UVB spectra were normalized
to 1 at 320 nm, whereas the UVA spectrum was normalized at 340 nm
to enable them to be compared.
Figure3
Sunscreen B absorbs more ultraviolet A than sunscreen A. The
spectral absorbance of sunscreens A and B was obtained using a
Labsphere UV-1000 SPF analyzer (Labsphere, North Sutton, New
Hampshire) with sunscreen applied at 2 mg per cm2 onto a quartz plate
substrate profiled with the topography of human skin derived from
casts of human test back skin.
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(SPF 16, good UVA protector with a UVA-PF of 4.5), its IPF
with a single ssUV exposure 72 h prior to antigen was 22.5
(95% confidence interval 20.3–25.1). Thus, despite having
very similar SPF, sunscreen B, with about twice the UVA
protection as sunscreen A, provided about double the
immunoprotection as sunscreen A. This proves that UVA
made a substantial contribution to ssUV-induced immuno-
suppression when antigen was applied 72 h following ssUV
exposure, despite UVA not being autonomously immuno-
suppressive at this time point. This further supports the
findings from the dose responses (Fig 1) that an interaction
between UVB and UVA is responsible for ssUV-induced
suppression to antigen challenge 72 h following ssUV
exposure.
Discussion
Previously, we have demonstrated significant suppression
of recall immunity to nickel using multiple daily subery-
themal ssUV exposures (Damian and Halliday, 2002). This
study has shown that a single ssUV exposure caused sig-
nificant suppression of the nickel CHS response in a time-
and concentration-dependent manner. In this study, we
found ssUV to be immunosuppressive when antigen chal-
lenge was 24–72 h following irradiation. ssUV caused sig-
nificant immunosuppression at doses as low as 1740 mJ
per cm2 72 h prior to antigen challenge. The average MED
of subjects with the range of skin types that we tested was
about 4000 mJ per cm2 (Kuchel et al, 2002, 2003; Fried-
mann et al, 2004) and therefore immunosuppression oc-
curred at ssUV doses lower than what was required to
cause sunburn. We have also recently shown that a single
exposure to 3420 mJ per cm2 ssUV 24 or 48 h prior to
elicitation of a DTH to tuberculin-purified protein resulted in
a suppressed response (Friedmann et al, 2004). Thus single
exposures to suberythemal doses of ssUV can suppress the
reactivation of memory CHS and DTH.
These studies have shown that within the first 24 h,
ssUV-induced immunosuppression is caused by the UVB
waveband, but by 48 h the UVA waveband contributes in-
dependently to ssUV immunosuppression with UVB main-
taining a role. By 72 h interactive effects between UVB and
UVA are the prime cause of ssUV-induced immunosup-
pression with the independent role of UVB diminishing and
UVA no longer being independently immunosuppressive. It
is therefore time dependent, which waveband within ssUV is
the main cause of sunlight-induced immunosuppression.
The ssUV spectrum approximated sunlight closely, and the
UVA spectrum contained no detectable UVB; however, the
UVB spectrum was contaminated with significant levels of
UVAII.
The transient immunosuppressive effect of UVA may ex-
plain why some studies have found that UVA is immuno-
protective rather than immunosuppressive (Reeve et al,
1998). Dose is also likely to be an important factor as we
have previously shown that whereas UVA doses within the
range used in this study are immunosuppressive in mice,
higher doses are immunoprotective (Byrne et al, 2002).
Previous studies of UVA-induced suppression of recall im-
munity to nickel in humans have shown that whereas 1942
mJ per cm2 UVA (within the range used in this study) was
immunosuppressive (Damian et al, 1999), 17,800 mJ per
cm2 UVA (4.5 times the highest dose used here) did not
modulate immunity (Kuchel et al, 2002). UVA is therefore a
complex immunomodulator that is both time and concen-
tration dependent. A single exposure to 8000 mJ per cm2
ssUV or UVA, doses nearly twice as high as those used in
this study, caused similar levels of suppression of recall
DTH to Candida albicans when the antigen challenge was
24 h following exposure in mice (Nghiem et al, 2001). This
shows that under these conditions UVA was crucial for
ssUV-induced immunosuppression and our data presented
here is in agreement with this, supplying evidence that UVA
is central for ssUV-induced suppression of recall immunity
in humans.
Interactions between UVA and other wavebands have
previously been reported. Doses of UVA too high to be in-
dependently immunosuppressive (17,800 mJ per cm2 daily
for 4 consecutive days) enhanced ssUV suppression of re-
call immunity to nickel in humans (Kuchel et al, 2002). In
these experiments, whereas UVA alone 72 h prior to antigen
challenge was not immunosuppressive, a sunscreen with
good UVA protection provided about twice the level of
immunoprotection as a sunscreen with poor UVA protec-
tion. This was despite these two sunscreens providing sim-
ilar levels of protection from UVB. Thus UVA made a vital
contribution to immunosuppression at 72 h via an interac-
tive effect with UVB.
It is unclear why UVB caused immunosuppression more
rapidly than UVA, with an interaction eventually occurring to
cause a more profound immunosuppression. It is possible
that different sequences of events are initiated by these
Figure 4
Immune protection factor determination for sunscreens with solar-
simulated ultraviolet (ssUV) 72 h prior to antigen challenge. ssUV
immunosuppression dose–response curves using four separate ssUV
doses 72 h prior to nickel challenge on skin that was unprotected (cir-
cles) or protected with the low ultraviolet A (UVA) protecting sunscreen
A (squares) or the high UVA protecting sunscreen B (triangles). Immuno-
suppression was calculated as the difference between an unirradiated
control site and each ssUV-irradiated test site as described in the leg-
end to Fig 2. A mean of 15 volunteers is shown. A line of best fit was
obtained using linear regression analysis (solid lines). The minimal
immunosuppressive dose was calculated from this line of best fit as
that ssUV dose that gave 30% immunosuppression in unprotected
skin, which was an immunosuppression of 21 erythemal index in this
experiment (dashed lines).
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wavebands that take different times to develop, but even-
tually interact with each other. UVB initiates systemic
immunosuppression in mice by forming the genetic lesion
cyclobutane pyrimidine dimers (CPD) in DNA (Kripke et al,
1992), and we have found CPD to also be involved in ssUV-
induced suppression of recall immunity to nickel in humans
(Halliday et al, 2004). But UVA mediates much of its damage
by production of reactive oxygen species (ROS) (Halliday,
2005), producing a different genetic lesion, 8-hydroxy-20-
deoxyguanine (Cadet et al, 2005). It is not known whether 8-
hydroxy-20-deoxyguanine initiates UVA-induced immuno-
suppression; however, ROS are involved in mice (Yuen et al,
2002) and humans (Clement-Lacroix et al, 1996; Kuchel
et al, 2003). It is possible that discrete downstream events
resulting from different initiating events such as distinct
types of genetic damage may be responsible for the differ-
ent times taken for UVB and UVA to suppress immunity to
antigen, and that these may eventually interact to make
ssUV more immunosuppressive than either waveband
alone. In support of this, UVB and UVA cause the produc-
tion of different but undefined immunosuppressive factors
from keratinocytes (Kim et al, 1990).
Alternatively, UVA and UVB may initiate similar immuno-
suppressive signals, with UVA taking longer than UVB at the
doses we used, and the combination of UVA and UVB
compounding ssUV immunosuppression at some point.
Trans-urocanic acid (UCA) is another photoreceptor that
isomerizes to cis-UCA in human skin upon excitation with
UVB and UVA (Kammeyer et al, 1995) and is a mediator of
UVB-induced immunosuppression (Norval and El-Ghorr,
2002). Whether it is also involved in UVA immunomodula-
tion is unclear. Langerhans cells (LC), dendritic antigen-pre-
senting cells of the epidermis, are the initial cells to induce
immunity in the epidermis. Damage to the function and
network of LC is important for UVB-induced suppression of
the induction of primary immunity (Ullrich, 2005). Although
the involvement of LC in suppression of recall immunity is
less clear, we find that immunosuppressive doses of ssUV
reduce the number of these cells in human skin (Kuchel
et al, 2003, 2005). UVA also reduces the number (Yuen et al,
2002) and function (Clement-Lacroix et al, 1996) of epider-
mal LC. It is possible that UVB and UVA both cause similar
molecular and cellular changes such as UCA isomerization
or LC damage but over different time courses with an even-
tual cumulative effect making ssUV more immunosup-
pressive than either waveband alone. IL-10, CPD, and
transferable antigen-specific NKT suppressor cells have
been shown to be at least partially responsible for both
ssUV and UVA suppression of recall DTH to C. albicans,
suggesting that at least some common suppressive mech-
anisms are activated by ssUV and UVA (Nghiem et al, 2002).
In summary, these studies show that UVB and UVA con-
tribute to sunlight-induced immunosuppression in humans,
but with different time courses. UVB causes the suppres-
sive effects of sunlight 24 h after irradiation, whereas UVA
and UVB independently are part of the cause of sunlight
immunosuppression at 48 h. Whereas UVA unaided is no
longer suppressive 72 h after irradiation, it cooperates with
UVB to make ssUV much more immunosuppressive than
either waveband alone. This interactive effect of UVA and
UVB is a more potent cause of immunosuppression than
either UVA or UVB alone. The different times required for
UVB, UVA, and their interactions to suppress recall immu-
nity to nickel in humans may be because of UVB and UVA
activating different molecular pathways that take dissimilar
times to develop, but ultimately interact. Alternatively, UVB
and UVA may instigate similar biological events, but to dis-
similar extents so that they take different times to develop
but eventually compound each other to have a greater ef-
fect than each waveband alone.
Materials and Methods
Subjects Ethical approval for this study was obtained from both
the Central Sydney Area Health Service and University of Sydney
Ethics Committees in accordance with the Helsinki guidelines.
Volunteers were recruited from the general population by adver-
tisement and gave their informed consent for the studies. Exclu-
sion criteria included sun exposure to the test sites for 4 wks prior
to the study and taking any anti-inflammatory or non-steroidal
medications. A total of 45 female nickel-allergic volunteers were
recruited for the UV-immunosuppression trials, and 15 females
were recruited for the sunscreen IPF studies. In the UVB trial the
age range was 18–66 y, one with skin type I, seven skin type II, five
skin type III, and two skin type IV. In the UVA trial the age range was
19–67 y, four with skin type I, eight skin type II, three skin type III. In
the ssUV trial the age range was 18–66 y, three with skin type I, six
skin type II, five skin type III, and one skin type IV. In the sunscreen
trial the age range was 18–61 y, six skin type II, six skin type III, and
three skin type IV.
UV source In these experiments, the UV source was an Oriel 1000
W solar simulator (Oriel, Stratford, Connecticut) equipped with twin
280–400 nm dichroic mirrors (Oriel) and an atmospheric attenua-
tion filter (Oriel) to produce an ssUV spectrum. To produce a UVA-
only spectrum, a UVB/UVC blocking filter (Oriel Serial no. 81017)
was used instead of the atmospheric attenuation filter. Two 280–
320 nm dichroic mirrors (Oriel) with the atmospheric attenuation
filter produced the UVB-only spectrum. These spectra are com-
pared with standard sunlight as defined by COLIPA (1994) in Fig 2.
Irradiance and spectra was monitored with a scanning spec-
trophotometer (Optronics, Orlando, Florida) and UV output mon-
itored daily with an IL1350 broadband radiometer using SED 038
(UVA) and SED 240 (UVB) detectors (International Light, Newbury-
port, Massachusetts) that were calibrated against the source with
the spectrophotometer. The integrated irradiance at the skin sur-
face for the solar-simulated spectrum was 3.4 mW per cm2 UVB,
6.9 mW per cm2 UVA II, and 19.2 mW per cm2 UVA I (UVA/UVB
ratio of 7.7). The ssUV spectrum was a close approximation to
sunlight, although it contained a lower ratio of UVA to UVB. The
UVA spectrum had a sharp cutoff at 320 nm containing no de-
tectable UVB, but was deficient in the 320–340 nm waveband
compared with sunlight. The shape of the UVB spectrum from 290
to 320 nm closely matched this portion of the sunlight and ssUV
spectra but was contaminated with some UVA (Fig 2).
Sunscreens The two sunscreens were purchased commercially in
Australia and were both labelled as broad spectrum. Sunscreen A
contained 7.5% zinc oxide, 8% octylmethoxycinnamate, and 2.5%
4-methylbenzylidene camphor. Sunscreen B contained 3% titani-
um dioxide, 4.2% 4-tert butyl-4-methoxybenzoylmethane, and
10.5% octocrylene. The same sunscreen application method and
amount (2 mg per cm2) used in previous in vivo SPF and IPF
studies were used (Poon et al, 2003). Sunscreen was applied at
least 15 min prior to irradiation and allowed to dry.
These sunscreens were chosen because we have previously
found that they have similar in vivo SPF but different IPF and UVA-
PF (Poon et al, 2003). Note that these IPF reported previously were
determined using repeated ssUV exposures on a daily basis for
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4 consecutive days. The SPF of sunscreen A was 15, but it is a poor
UVA protector with a Diffey critical wavelength of 368 nm, a Boots
UVA ratio of 0.33, and a UVA-PF of 2.3. From previous IPF studies
using multiple UV irradiations it had an IPF of 9.5. Sunscreen B had
a similar in vivo SPF of 16, but better UVA protection with a Diffey
critical wavelength of 383 nm, a Boots UVA ratio of 0.85 and a
UVA-PF of 4.5. Its IPF from previous studies was 20.7. It is im-
portant to note that this study was performed with the same UV
source as the previous study where the SPF and UVA protection
factors of the sunscreens were determined, but this study used a
single, rather than multiple ssUV exposures to determine the IPF.
UV immunosuppression time courses and dose respons-
es Determination of UV-induced suppression of nickel CHS in hu-
mans was as detailed previously (Damian and Halliday, 2002)
except that a single exposure to UV was used. Nickel-allergic vol-
unteers had three separate 6  2 cm areas on their lower midbacks
irradiated with a single exposure 24, 48, or 72 h prior to nickel
challenge. Each area was demarcated into three test sites that each
received a different dose of UV. Thus, there were nine UV-irradiated
test sites each of which received one of three UV doses at one of
three times prior to antigen challenge. There was also a separate
unirradiated control site. The areas were irradiated on different days
(Tuesday, Wednesday, or Thursday) so that nickel patch testing was
at the same time (Friday). Nine millimeters Finn Chambers (Epitest,
Tuusula, Finland) containing nickel sulfate (NiSO4  6H2O) in a pet-
rolatum base were applied to each of the test sites and the unir-
radiated control. Each volunteer had the same concentration of
nickel applied to all test sites with concentrations being individu-
alized for each volunteer (such that the dose that produced con-
fluent erythema without vesiculation in initial testing of that subject).
These nickel patches were then removed 48 h later, with the nickel-
induced CHS being quantitated after a further 24 h 72 h following
nickel challenge. Objective measurement of the nickel-induced
CHS responses was obtained using a reflectance spectrometer/
erythema meter (Diastron, Hampshire, UK). The nickel-induced
erythema index (EI) for each test site was calculated as the differ-
ence of the average of three readings taken at each test site and the
average of three readings taken of adjacent skin.
This same experimental procedure was repeated on different
groups of volunteers receiving different UV spectra (UVB, UVA, or
ssUV). For the UVB spectrum, the UVB doses contained within the
ssUV spectrum experiment were used (200, 300, and 500 mJ per
cm2 UVB). The doses used in the UVA only experiment were the
UVA components of the ssUV experiment (1540, 2310, or 3850 mJ
per cm2 UVA; 7.7 times the UVB doses).
Data analysis Immunosuppression was calculated at each test
site by subtracting the nickel-induced EI of the test site from that
of the unirradiated control. The results of each test site in 15
volunteers for each UV spectrum were pooled, and the average
immunosuppression at each test site was calculated.
To determine whether a particular dose of UVB, UVA, or ssUV
caused a significant level of immunosuppression, the nickel-in-
duced EI at the appropriate test site was compared with the un-
irradiated positive control in the same individual using a paired
two-tailed Student’s t test. Immunosuppression was considered
significant if po0.05.
For a particular UV spectrum, differences in the dose responses
at each time between irradiation and antigen challenge were
analyzed by repeated-measures ANOVA.
MISD and IPF were calculated as described previously (Poon
et al, 2003). The average immunosuppression with and without
sunscreen protection in the group of 15 volunteers (calculated as
described above) was plotted against ssUV dose and linear re-
gression analysis was used to determine the dose of ssUV that
caused 30% immunosuppression (compared with the unirradiated
control sites). This was deemed to be the MISD. The IPF for each
sunscreen was the ratio of the MISD with sunscreen protection to
the MISD without protection. Ninety-five percent confidence inter-
vals were calculated using 10,000 bootstrap samples for each
sunscreen.
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